Free Trial

ConvaTec Group (CTEC) Competitors

GBX 247.60
-4.00 (-1.59%)
(As of 06:36 AM ET)

CTEC vs. HIK, HCM, INDV, SN, AMS, TSTL, BVC, SPEC, CNSL, and GNS

Should you be buying ConvaTec Group stock or one of its competitors? The main competitors of ConvaTec Group include Hikma Pharmaceuticals (HIK), HUTCHMED (HCM), Indivior (INDV), Smith & Nephew (SN), Advanced Medical Solutions Group (AMS), Tristel (TSTL), BATM Advanced Communications (BVC), INSPECS Group (SPEC), Cambridge Nutritional Sciences (CNSL), and Genus (GNS). These companies are all part of the "medical" sector.

ConvaTec Group vs.

ConvaTec Group (LON:CTEC) and Hikma Pharmaceuticals (LON:HIK) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, community ranking, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

Hikma Pharmaceuticals received 446 more outperform votes than ConvaTec Group when rated by MarketBeat users. Likewise, 70.56% of users gave Hikma Pharmaceuticals an outperform vote while only 66.54% of users gave ConvaTec Group an outperform vote.

CompanyUnderperformOutperform
ConvaTec GroupOutperform Votes
352
66.54%
Underperform Votes
177
33.46%
Hikma PharmaceuticalsOutperform Votes
798
70.56%
Underperform Votes
333
29.44%

67.2% of ConvaTec Group shares are owned by institutional investors. Comparatively, 37.6% of Hikma Pharmaceuticals shares are owned by institutional investors. 20.0% of ConvaTec Group shares are owned by insiders. Comparatively, 30.6% of Hikma Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

ConvaTec Group presently has a consensus target price of GBX 307.17, indicating a potential upside of 24.06%. Hikma Pharmaceuticals has a consensus target price of GBX 2,050, indicating a potential upside of 7.40%. Given ConvaTec Group's stronger consensus rating and higher probable upside, analysts clearly believe ConvaTec Group is more favorable than Hikma Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ConvaTec Group
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
Hikma Pharmaceuticals
0 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.40

Hikma Pharmaceuticals has a net margin of 6.61% compared to ConvaTec Group's net margin of 6.08%. Hikma Pharmaceuticals' return on equity of 8.81% beat ConvaTec Group's return on equity.

Company Net Margins Return on Equity Return on Assets
ConvaTec Group6.08% 7.89% 4.79%
Hikma Pharmaceuticals 6.61%8.81%8.46%

In the previous week, Hikma Pharmaceuticals had 1 more articles in the media than ConvaTec Group. MarketBeat recorded 1 mentions for Hikma Pharmaceuticals and 0 mentions for ConvaTec Group. ConvaTec Group's average media sentiment score of 1.02 beat Hikma Pharmaceuticals' score of 0.91 indicating that ConvaTec Group is being referred to more favorably in the media.

Company Overall Sentiment
ConvaTec Group Positive
Hikma Pharmaceuticals Positive

ConvaTec Group has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500. Comparatively, Hikma Pharmaceuticals has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500.

ConvaTec Group pays an annual dividend of GBX 5 per share and has a dividend yield of 2.0%. Hikma Pharmaceuticals pays an annual dividend of GBX 57 per share and has a dividend yield of 3.0%. ConvaTec Group pays out 10,000.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Hikma Pharmaceuticals pays out 8,507.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Hikma Pharmaceuticals is clearly the better dividend stock, given its higher yield and lower payout ratio.

Hikma Pharmaceuticals has higher revenue and earnings than ConvaTec Group. Hikma Pharmaceuticals is trading at a lower price-to-earnings ratio than ConvaTec Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ConvaTec Group£2.14B2.37£130.30M£0.054,952.00
Hikma Pharmaceuticals£2.88B1.47£190M£0.672,853.73

Summary

Hikma Pharmaceuticals beats ConvaTec Group on 12 of the 20 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTEC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CTEC vs. The Competition

MetricConvaTec GroupMedical Instruments & Supplies IndustryMedical SectorLON Exchange
Market Cap£5.08B£2.86B£5.01B£1.41B
Dividend Yield1.93%1.92%2.81%11.82%
P/E Ratio4,952.00332.31163.831,691.82
Price / Sales2.37212.602,445.48302,110.83
Price / Cash17.01124.3032.6132.84
Price / Book2.982.865.082.72
Net Income£130.30M£93.20M£104.31M£164.50M
7 Day Performance-2.52%0.58%-0.59%0.01%
1 Month Performance-2.21%1.44%2.58%9.37%
1 Year Performance19.50%-6.06%5.31%18.11%

ConvaTec Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HIK
Hikma Pharmaceuticals
0.6651 of 5 stars
GBX 1,932
-2.1%
GBX 2,068.75
+7.1%
+2.9%£4.29B£2.88B2,841.189,100
HCM
HUTCHMED
0 of 5 stars
GBX 315
-2.8%
N/A+40.8%£2.69B£838M3,500.001,988Gap Down
INDV
Indivior
1.3843 of 5 stars
GBX 1,328
-0.4%
GBX 2,515
+89.4%
-3.1%£1.79B£1.12B44,266.671,000Gap Up
SN
Smith & Nephew
2.659 of 5 stars
GBX 1,019.50
-0.3%
GBX 1,346.20
+32.0%
-20.1%£8.91B£5.55B4,247.9218,452News Coverage
High Trading Volume
AMS
Advanced Medical Solutions Group
2.2704 of 5 stars
GBX 213
flat
GBX 300
+40.8%
-5.9%£456.27M£126.21M3,042.86800
TSTL
Tristel
0 of 5 stars
GBX 440
flat
GBX 390
-11.4%
+25.7%£209.18M£39.49M3,666.67208High Trading Volume
BVC
BATM Advanced Communications
0 of 5 stars
GBX 18.18
-1.2%
N/A-26.6%£79.28M£122.83M2,800.00980
SPEC
INSPECS Group
0 of 5 stars
GBX 72.50
-2.0%
N/A-37.1%£73.71M£203.29M-7,250.001,673
CNSL
Cambridge Nutritional Sciences
0 of 5 stars
N/AN/AN/A£9.40M£9.05M-395.5091
GNS
Genus
0 of 5 stars
GBX 1,872
-0.4%
N/A-28.2%£1.24B£673.10M3,670.593,500

Related Companies and Tools

This page (LON:CTEC) was last updated on 5/29/2024 by MarketBeat.com Staff

From Our Partners